Advisor
Eli Lilly
Indianapolis, Indiana
Sabine Wenzel, Ph.D., joined Eli Lilly and Company as an Advisor in 2022. In her role she oversees large molecule assay development with a strong focus on Gene Therapy modalities, for which she is the technical lead of the content methods. Further, she supports method installations at GMP release testing sites for clinical support. Prior to joining Lilly, Dr. Wenzel had gained over a decade worth of experience on molecular and biophysical analysis of key factors in eukaryotic transcription at academic institutions such as Vanderbilt University, Nashville, TN, and Indiana University School of Medicine, Indianapolis, IN. She received her Ph.D. in Biochemistry from the University of Bayreuth, Germany.
Disclosure information not submitted.
Transferring an AAV Genome Titer Method - Lessons and Keys to Success
Wednesday, July 24, 2024
2:05 PM – 2:35 PM CST